6 min. read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles